Rucaparib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Ovarian Cancer, Metastatic Castration-Resistant Prostate Cancer, Prostate Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (1)
EU
  • Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.
Product first approved 2018EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (8)
Metastatic Castration-Resistant Prostate Cancer
NCT04676334 · pharmaand GmbH
2021-03-22 – 2023-03-08 · Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Other Solid Tumor
What this study did
Ovarian Cancer
NCT04227522 · North Eastern German Society of Gynaecological Oncology
2020-06-08 – 2024-07-01 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Clear Cell Carcinoma
What this study did
Prostate Cancer
NCT04455750 · Alliance for Clinical Trials in Oncology
2021-10-14 – 2027-09 · Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
What this study did
Other / comorbidity
NCT03768063 · Hoffmann-La Roche
2019-02-28 – 2028-07-05 · Cancer
What this study did
Phase 2 (29)
Metastatic Castration-Resistant Prostate Cancer
NCT03442556 · University of Washington
2018-08-24 – 2025-06-04 · ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Homologous Recombination Deficiency, Prostate Carcinoma Metastatic in the Bone, PSA Level Greater Than or Equal to Two, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
What this study did
NCT03338790 · Bristol-Myers Squibb
2017-12-19 – 2025-01-10 · Prostate Cancer
What this study did
Ovarian Cancer
NCT02873962 · Dana-Farber Cancer Institute
2016-11-10 – 2027-01 · Peritoneal Cancer, Ovarian Cancer, Fallopian Tube Cancer
What this study did
NCT01891344 · pharmaand GmbH
2013-10-30 – 2021-09-28 · Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
What this study did
NCT03824704 · pharmaand GmbH
2019-08-23 – 2020-08-24 · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, High Grade Serous Carcinoma, Endometrioid Adenocarcinoma
What this study did
NCT00664781 · Cancer Research UK
2007-12 – 2015-01 · brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer, Ovarian Cancer
What this study did
Prostate Cancer
NCT03413995 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2018-09-10 – 2024-09-12 · Prostate Cancer Metastatic
What this study did
NCT03533946 · University of Utah
2019-05-20 – 2023-01-12 · Prostate Cancer
What this study did
Other / comorbidity
NCT03899155 · Bristol-Myers Squibb
2019-08-09 – 2029-08-25 · Cancer
What this study did
NCT02925234 · The Netherlands Cancer Institute
2016-08 – 2027-12 · Cancer, Tumors, Neoplasm, Neoplasia
What this study did
NCT02678182 · Royal Marsden NHS Foundation Trust
2015-02 – 2027-06 · Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Gastro-oesophageal Junction, Adenocarcinoma of the Stomach
What this study did
NCT04624178 · Memorial Sloan Kettering Cancer Center
2020-11-05 – 2026-11-16 · Leiomyosarcoma
What this study did
NCT03694262 · Medical College of Wisconsin
2019-07-19 – 2026-03-10 · Endometrial Cancer, Uterine Carcinosarcoma
What this study did
NCT03617679 · University of Colorado, Denver
2019-03-06 – 2026-02-27 · Metastatic Endometrial Cancer
What this study did
NCT03845296 · SWOG Cancer Research Network
2019-04-16 – 2024-09-21 · Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Loss of Heterozygosity, Lung Non-Small Cell Squamous Carcinoma, Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT03639935 · University of Michigan Rogel Cancer Center
2019-03-28 – 2024-04-30 · Biliary Tract Cancer
What this study did
NCT03654833 · University of Leicester
2019-01-28 – 2024-03-15 · Mesothelioma, Malignant
What this study did
NCT04276376 · Gustave Roussy, Cancer Campus, Grand Paris
2019-04-12 – 2023-12-12 · Solid Tumor
What this study did
NCT03476798 · University of Oklahoma
2018-06-29 – 2023-09-29 · Cervical Cancer, Endometrial Cancer
What this study did
NCT03140670 · Abramson Cancer Center at Penn Medicine
2017-09-05 – 2023-08-07 · Pancreatic Cancer
What this study did
NCT03958045 · Zhonglin Hao
2019-09-04 – 2022-11-15 · Small Cell Lung Cancer
What this study did
NCT04171700 · pharmaand GmbH
2020-01-16 – 2022-07-15 · Solid Tumor
What this study did
NCT02935634 · Bristol-Myers Squibb
2016-11-29 – 2022-05-11 · Advanced Gastric Cancer
What this study did
NCT03397394 · pharmaand GmbH
2018-06-01 – 2020-01-15 · Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Renal Pelvis Carcinoma, Ureter Carcinoma, Urinary Bladder Carcinoma, Urethra Carcinoma, Muscle Invasive Bladder Cancer
What this study did
NCT02505048 · UNICANCER
2016-03 – 2019-12 · Metastatic Breast Cancer
What this study did
NCT03795272 · Nordic Society of Gynaecological Oncology - Clinical Trials Unit
2019-10-01 – 2019-10-10 · Cervical Cancer
What this study did
NCT01074970 · Hoosier Cancer Research Network
2010-02 – 2018-12-15 · Breast Cancer
What this study did
NCT02042378 · pharmaand GmbH
2014-04 – 2016-05 · Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
What this study did
Phase 1/2 (11)
Metastatic Castration-Resistant Prostate Cancer
NCT04253262 · Brown University
2020-04-03 – 2027-01 · Metastatic Castration-resistant Prostate Cancer
What this study did
Ovarian Cancer
NCT03992131 · pharmaand GmbH
2019-06-28 – 2022-04-22 · Ovarian Cancer, Triple-negative Breast Cancer, Urothelial Carcinoma, Solid Tumor
What this study did
NCT01482715 · pharmaand GmbH
2011-11 – 2019-05 · Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Advanced Solid Tumor With Evidence of Germline or Somatic BRCA
What this study did
Prostate Cancer
NCT03572478 · University of Chicago
2018-08-14 – 2020-10-01 · Prostate Cancer, Endometrial Cancer
What this study did
Other / comorbidity
NCT03337087 · Academic and Community Cancer Research United
2018-11-02 – 2025-08-09 · Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Digestive System Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
What this study did
NCT03559049 · University of Michigan Rogel Cancer Center
2018-12-24 – 2025-05-01 · Stage IV Non-small Cell Lung Cancer
What this study did
NCT03462212 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS
2021-03-17 – 2025-03-01 · Advanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer
What this study did
NCT04209595 · National Cancer Institute (NCI)
2020-04-08 – 2025-02-24 · Small Cell Lung Cancer, Extra-Pulmonary Small Cell Carcinomas
What this study did
NCT03995017 · University of Kansas Medical Center
2020-01-09 – 2024-12 · Esophagus Cancer, Adenocarcinoma, Stomach Cancer, Adenocarcinoma
What this study did
NCT02711137 · Incyte Corporation
2016-05-18 – 2019-02-13 · Solid Tumors
What this study did
Phase 1 (12)
Metastatic Castration-Resistant Prostate Cancer
NCT04179396 · pharmaand GmbH
2019-12-05 – 2023-01-18 · Metastatic Castration Resistant Prostate Cancer
What this study did
Ovarian Cancer
NCT03552471 · Ohio State University Comprehensive Cancer Center
2018-07-12 – 2022-12-19 · BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Uterine Serous Carcinoma, Recurrent Uterine Carcinosarcoma, Platinum Resistant Ovarian Cancer
What this study did
Prostate Cancer
NCT03840200 · Hoffmann-La Roche
2019-06-12 – 2022-01-04 · Breast Cancer, Prostate Cancer, Ovarian Cancer
What this study did
Other / comorbidity
NCT03542175 · Memorial Sloan Kettering Cancer Center
2018-05-23 – 2025-09-10 · Breast Cancer
What this study did
NCT03499444 · pharmaand GmbH
2018-02-06 – 2022-04-13 · Advanced Solid Tumor
What this study did
NCT03911453 · University of Arizona
2019-04-19 – 2021-07-16 · Breast Cancer
What this study did
NCT03954366 · pharmaand GmbH
2019-04-25 – 2021-06-09 · Neoplasms
What this study did
NCT03318445 · Pamela Munster
2018-01-12 – 2021-03-01 · Solid Tumor, Unspecified, Adult
What this study did
NCT03521037 · pharmaand GmbH
2018-02-27 – 2021-02-24 · Neoplasms
What this study did
NCT03101280 · Hoffmann-La Roche
2017-04-27 – 2020-08-11 · Gynecologic Neoplasms
What this study did
NCT02740712 · pharmaand GmbH
2016-04 – 2019-09 · Neoplasms
What this study did
NCT02986100 · pharmaand GmbH
2016-11 – 2018-09 · Solid Tumor
What this study did

Competitive landscape

This drug's own stage for Metastatic Castration-Resistant Prostate Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Rucaparib: this drugApprovedSmall moleculePARP (poly ADP-ribose polymerase) enzymes, PARP1/2Partial signalNo reviewed efficacy summary in this indication
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
OlaparibApprovedSmall moleculePARPnot yet gradedNo reviewed efficacy summary in this indication
TalazoparibApprovedSmall moleculePARPnot yet gradedNo reviewed efficacy summary in this indication
Elfetabart DrozuntecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
FluzoparibPhase 3Small moleculePARP (poly ADP-ribose polymerase), specifically PARP-1not yet gradedNo reviewed efficacy summary in this indication
HRS-4357Phase 3UndisclosedPSMAnot yet gradedNo reviewed efficacy summary in this indication
Ifinatamab DeruxtecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
MevrometostatPhase 3Small moleculeEZH2not yet gradedNo reviewed efficacy summary in this indication
OpevesostatPhase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
PasritamigPhase 3Multispecific antibody—not yet gradedNo reviewed efficacy summary in this indication
Zadavotide GuraxetanPhase 3Radioconjugate (actinium-225)PSMAnot yet gradedNo reviewed efficacy summary in this indication
LuxdegalutamidePhase 2Small moleculeAndrogen receptor, Androgen receptor (degrader)not yet gradedNo reviewed efficacy summary in this indication
ABBV-969Phase 1UndisclosedPSMA / STEAP1not yet gradedNo reviewed efficacy summary in this indication
AKY-2519Phase 1RadiopharmaceuticalB7-H3-targeted radioligand therapynot yet gradedNo reviewed efficacy summary in this indication
BPX-601Phase 1Cell therapyPSCAnot yet gradedNo reviewed efficacy summary in this indication
RG6852
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Rucaparib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
January 2027 (1)
Phase 1/2Metastatic Castration-Resistant Prostate CancerActive not recruiting
Est. primary completion 2027-01 · NCT04253262 · CT.gov ↗
What to watch
March 2027 (1)
Phase 3Prostate CancerActive not recruiting
Est. primary completion 2027-03-15 · NCT04455750 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Cancer, Tumors, Neoplasm, NeoplasiaRecruiting
Est. primary completion 2027-09 · NCT02925234 · CT.gov ↗
What to watch
2028 (1)
July 2028 (1)
Phase 3CancerActive not recruiting
Est. primary completion 2028-07-05 · NCT03768063 · CT.gov ↗
What to watch
2029 (1)
August 2029 (1)
Phase 2CancerRecruiting
Est. primary completion 2029-08-25 · NCT03899155 · CT.gov ↗
What to watch

See the full readout calendar ↗